The Food and Drug Administration approved daratumumab and hyaluronidase-fihj, or Darzalex Faspro, from Janssen Biotech, for adults with high-risk smoldering multiple myeloma, the agency announced.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- FDA awards second batch of National Priority Vouchers
- Johnson & Johnson announces FDA approval of Caplyta
- Zimmer Biomet price target lowered to $112 from $122 at BTIG
- M&A: Diaper Group Kimberly-Clark Leaks 15% After $48.7B Purchase of Tylenol Maker Kenvue
- Trump Weekly: Trump cuts China tariffs in deal on fentanyl, rare earths